The Danish drugmaker unveiled a series of initiatives to increase access to Wegovy and clamp down on use of the knock-off ...

Novo Nordisk's GLP-1 agonist Ozempic (semaglutide) has been available in China for diabetes since 2021, and the Wegovy formulation ... GIP agonist tirzepatide was approved for diabetes in May ...

The United States and China announced this morning that they ... lost roughly 50 percent more weight than people who took Wegovy, per The Associated Press. It could significantly cut Medicaid ...

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...